Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims.

1.-14. (Canceled).

- 15. (Withdrawn) A method of making an isolated polypeptide comprising:
 - (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
 - (b) recovering said polypeptide.

Claim 16-23. (Canceled).

- 24. (Previously Presented): An isolated protein comprising amino acid residues 29 to 453 of SEQ ID NO:3177.
- 25. (Previously Presented): The isolated protein of claim 24 which comprises amino acid residues 2 to 453 of SEQ ID NO:3177.
- 26. (Previously Presented): The isolated protein of claim 24 which comprises amino acid residues 1 to 453 of SEQ ID NO:3177.
- 27. (Previously Presented): The protein of claim 24 which further comprises a heterologous polypeptide sequence.
- 28. (Previously Presented): A composition comprising the protein of claim 24 and a pharmaceutically acceptable carrier.
- 29. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 24 by a cell; and
 - (b) recovering said protein.
- 30. (Previously Presented): An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.

Application No.: 09/950,083 14 Docket No.: PS-805

- 31. (Previously Presented): The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960, excepting the N-terminal methionine.
- 32. (Previously Presented): The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.
- 33. (Previously Presented): The protein of claim 30 which further comprises a heterologous polypeptide sequence.
- 34. (Previously Presented): A composition comprising the protein of claim 30 and a pharmaceutically acceptable carrier.
- 35. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 30 by a cell; and
 - (b) recovering said protein.
- 36. (Previously Presented): An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 1 to 453 of SEQ ID NO:3177.
- 37. (Previously Presented): The isolated protein of claim 36, wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 453 of SEQ ID NO:3177.
- 38. (Previously Presented): The protein of claim 36 which further comprises a heterologous polypeptide sequence.
- 39. (Previously Presented): A composition comprising the protein of claim 36 and a pharmaceutically acceptable carrier.
- 40. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 36 by a cell; and
 - (b) recovering said protein.

- 41. (Previously Presented): An isolated protein comprising a polypeptide sequence which is at least 90% identical to the complete polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.
- 42. (Previously Presented): The isolated protein of claim 41, wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.
- 43. (Previously Presented): The protein of claim 41 which further comprises a heterologous polypeptide sequence.
- 44. (Previously Presented): A composition comprising the protein of claim 41 and a pharmaceutically acceptable carrier.
- 45. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 41 by a cell; and
 - (b) recovering said protein.
- 46. (Previously Presented): An isolated protein consisting of at least 30 contiguous amino acid residues of amino acid residues 29 to 453 of SEQ ID NO:3177.
- 47. (Previously Presented): The isolated protein of claim 46 which consists of at least 50 contiguous amino acid residues of amino acid residues 29 to 453 of SEQ ID NO:3177.
- 48. (Previously Presented): The protein of claim 46 which further comprises a heterologous polypeptide sequence.
- 49. (Previously Presented): A composition comprising the protein of claim 46 and a pharmaceutically acceptable carrier.
- 50. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 46 by a cell; and

- (b) recovering said protein.
- 51. (Previously Presented): An isolated protein consisting of at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.
- 52. (Previously Presented): The isolated protein of claim 51 which consists of at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HDPKC55 cDNA contained in ATCC Deposit No. 203960.
- 53. (Previously Presented): The protein of claim 51 which further comprises a heterologous polypeptide sequence.
- 54. (Previously Presented): A composition comprising the protein of claim 51 and pharmaceutically acceptable carrier.
- 55. (Previously Presented): An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 51 by a cell; and
 - (b) recovering said protein.